# ViaLase

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vialase

- Industry: Medical Devices & Equipment
- Headquarters: Aliso Viejo, US
- Website: www.vialase.com
- Total disclosed funding: $38M
- Latest round: Series C (Mar 25, 2024)
- Investors on record: 3

## About

Based in California, US, and founded in 2019 by CEO Tibor Juhasz, ViaLase, Inc., a.k.a. ViaLase, operates as an ophthalmic med-tech company that focuses on designing, developing, and manufacturing femtosecond lasers for ophthalmic surgery for refractive, cataract, and glaucoma patients. In April 2024, ViaLase, Inc. raised USD 40 million in a Series C funding from Venture Investors Health Fund, Arboretum Ventures, Falcon Vision, KKR, and Flying L Partners.

The company provides ViaLuxe™ Laser System, along with ViaLens™ Patient Interface, ViaVue™ Gonio Camera, ViaLuxe™ Laser, and ViaLink™ to reduce IOP using femtosecond laser precision and micron-accurate gonio imaging to non-invasively create customized drainage channels through the trabecular meshwork. The synergy between femtosecond laser technology and gonio imaging delivers visibility and precision, offering doctors detailed, real-time views of tissue structures on a micron scale.

ViaLase plans to use its proceeds from April 2024 funding to ensure its focus on advancing its clinical, regulatory, and commercial milestones.

## Funding rounds

- Series C, Mar 25, 2024, $38M — Venture Investors, Arboretum Ventures, Falcon Vision

## Investors

- Venture Investors — Series C
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series C
- Falcon Vision — Series C